Tool Co-Developed with Lincoln Technologies and FDA Helps Agency to Assess the Safety of Drugs
Waltham, MA – September 8, 2005 – Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the successful completion of recently acquired Lincoln Technologies' Cooperative Research and Development Agreement (CRADA) with the FDA to develop advanced analytical tools for drug safety risk assessment. The project, which began in March of 2003 and involved participation by both the FDA Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), resulted in the development of the Web Visual Data Mining Environment (WebVDME) 5.1 feature set and user interface. FDA is implementing Lincoln's WebVDME system for production and use by safety evaluators and epidemiologists in CDER's Division of Drug Risk Evaluation (DDRE) and CBER's Division of Epidemiology.
The success of Lincoln's CRADA with the FDA is a result of several years of work by the FDA evaluating data mining and associated data visualization techniques as a tool to help safety evaluators analyze spontaneous reports of adverse reactions pertaining to drugs, biologics, and vaccines. Lincoln's data mining technology and specialized graphic visualization tools have been used by the FDA with its Adverse Event Reporting System (AERS) and Vaccine Adverse Event Reporting System (VAERS) database of voluntary adverse reaction reports to help identify unexpectedly frequent combinations of drugs and events and to organize, identify, and interpret patterns in the data.
"We are pleased that our longstanding collaboration with the FDA has resulted in the addition of new data mining capabilities to complement their present pharmacovigilance practices," said Chan Russell, president of Lincoln Technologies. "In addition, our recent merger with Phase Forward brings the additional resources and operational infrastructure necessary to continue to support and build upon the use of WebVDME at the FDA."
The FDA is exploring other areas in which WebVDME may prove useful for safety surveillance, including medication error monitoring, assessment of safety in clinical trials, and signal detection in electronic longitudinal medical records.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.